JAZZNasdaqPharmaceutical PreparationsUS GAAP · USD

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology. It commercializes products such as Xywav, Epidiolex/Epidyolex, Zepzelca, Rylaze, Vyxeos, Defitelio, Ziihera and Modeyso, while also advancing a pipeline of product candidates and pursuing acquisitions and in-licensing to expand its portfolio.

Kysy yhtiöstä
Liikevaihto4 268milj. USD
+4,9 %v/v
Liikevoitto (EBIT)−430milj. USD
−160,0 %v/v
EBIT-marginaali−10,1%
−27,7 %-yks.v/v
Nettotulos−356milj. USD
−163,6 %v/v
Vapaa kassavirta1 297milj. USD
−4,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−1 00001 0002 0003 0004 0005 000milj. USD2020: 2 364 milj. USD2020: EBIT 378 milj. USD20202021: 3 094 milj. USD2021: EBIT 170 milj. USD20212022: 3 659 milj. USD2022: EBIT −66 milj. USD20222023: 3 834 milj. USD2023: EBIT 579 milj. USD20232024: 4 069 milj. USD2024: EBIT 717 milj. USD20242025: 4 268 milj. USD2025: EBIT −430 milj. USD20254 268−430
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Jazz Pharmaceuticals plc

Liiketoiminta

Osuus liikevaihdosta
Neuroscience medicines68 %

Commercial products for sleep disorders and epilepsy, including oxybate therapies and cannabidiol-based treatment.

Oncology medicines26 %

Hospital and specialty oncology products used in hematology and solid tumor settings.

Royalties and contract revenues6 %

Royalty income and other contract-based revenues tied to partnered or licensed assets.

Tuotteet

Raportoitu · osuus liikevaihdosta
36,2%23,9%10,1%16,1%FY2024100 %
  • Xywav36,2 %
  • Epidiolex Epidyolex23,9 %
  • Rylaze Enrylaze10,1 %
  • Zepzelca7,9 %
  • Xyrem5,7 %
  • Muut16,1 %

Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Jazz sells primarily to specialty pharmacies, specialty distributors, wholesalers, hospitals and institutional customers, with some products shipped directly to patients through certified pharmacies. Its customer base is concentrated in specialty care settings such as neurology, sleep medicine, hematology and oncology, where access, reimbursement and patient support are critical to adoption. In Europe, Canada and Australia, it also works through wholesalers, distributors and local medical affairs teams depending on market authorization and local regulation.

Specialty pharmacies

Buy Xywav, Xyrem, Epidiolex and Modeyso for controlled dispensing and direct patient shipment.

Hospitals and oncology institutions

Buy Defitelio, Vyxeos, Zepzelca, Rylaze and Ziihera for inpatient and outpatient cancer care.

Wholesalers and specialty distributors

Purchase and distribute products across the U.S. and international markets to maintain access.

Patients via certified channels

End users of oxybate and epilepsy therapies, reached through specialty pharmacy and reimbursement support.

International healthcare systems

Buy through local distributors, named-patient programs and market authorization pathways in Europe and Canada.

Strategia

Jazz is prioritizing commercial execution in neuroscience and oncology while expanding its pipeline through internal R&D, clinical trials and external product acquisition or in-licensing. Management also emphasizes disciplined capital deployment, including strategic transactions and selective financing, to build a broader portfolio of durable, differentiated assets. The strategy is designed to reduce dependence on any single product franchise and support long-term growth through launches, lifecycle management and portfolio expansion.

Commercialize and expand current marketed productsLyhyt aikaväli

Existing products fund the business and support near-term growth while the company builds its pipeline.

Advance R&D and clinical developmentKeskipitkä aikaväli

Pipeline success is needed to replace mature assets and create longer-duration growth drivers.

Acquire or in-license differentiated assetsKeskipitkä aikaväli

External deal-making is a core path to portfolio expansion and diversification.

Maantiede

Q1/2026

Jazz operates directly in the U.S., Europe, Australia and Canada, and uses distributors in other key global markets. The U.S. is the core commercial market, while Europe and Canada are important for Defitelio, Vyxeos and Epidyolex/Epidiolex, and Australia is part of the direct commercialization footprint. The company also has a large international workforce, with about 47% of employees outside the U.S., mainly in the U.K., Ireland and the EU.

USA90 %
Europe8,6 %
Other countries (US filing)1,6 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Jazz is exposed to concentration risk in its oxybate franchise and to execution risk around launching and scaling newer oncology products. Because its business depends on specialty channels, reimbursement, regulatory approvals and controlled distribution, pricing, access and compliance issues can materially affect demand and margins. The company also faces typical biopharma risks from clinical failure, patent and competition pressure, cybersecurity incidents and integration risk from acquisitions.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Loss of oxybate franchise revenue1Government investigations and drug pricing scrutiny2Clinical development and regulatory approval failure3Cybersecurity and IT incidents4Acquisition and integration risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Loss of oxybate franchise revenueVaikutus: KorkeaTodennäköisyys: Korkea

    The company states that inability to maintain oxybate revenues would materially hurt business and growth prospects.

    Kohdistuu: Xywav and Xyrem

  2. Government investigations and drug pricing scrutinyVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Oversight can create legal expense, reputational damage and reduced market acceptance.

    Kohdistuu: U.S. pricing and compliance practices

  3. Clinical development and regulatory approval failureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Pipeline value depends on successful trials and timely approvals for new products.

    Kohdistuu: Oncology and neuroscience candidates

  4. Cybersecurity and IT incidentsVaikutus: KeskitasoTodennäköisyys: Matala

    A breach or outage could interrupt operations, expose data and weaken internal controls.

    Kohdistuu: Global commercial and R&D systems

  5. Acquisition and integration riskVaikutus: KeskitasoTodennäköisyys: Matala

    Deal-making is central to strategy, but integration issues can impair returns and liquidity.

    KohdistuuProduct acquisitions and in-licensingIncluding Chimerix
Kysy Clarifolta: Jazz Pharmaceuticals plc

Kirjanpito

Harkinnanvaraiset erät
Revenue deductions and reserves

Gross sales are reduced by estimated rebates, chargebacks, returns and patient support, affecting reported net revenue.

Vaikutus: Can materially change quarterly product sales and margins

Point-in-time revenue recognition

Product sales are recognized on transfer of control, including consignment-related timing.

Vaikutus: Can shift revenue between periods based on shipment and patient dispensing timing

Goodwill impairment

The company reported $1.8 billion of goodwill and tests it annually for impairment.

Vaikutus: A write-down would reduce earnings and signal weaker acquisition value

Acquisition-related contingent consideration and royalties

Recent acquisitions added milestone payments and royalty obligations.

Vaikutus: Affects liabilities, future cash outflows and earnings presentation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Ionis Pharmaceuticals, Inc

IONS · Pharmaceutical Preparations

Vertex Pharmaceuticals Incorporated

VRTX · Pharmaceutical Preparations

Xenon Pharmaceuticals Inc.

XENE · Pharmaceutical Preparations

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

AstraZeneca PLC

AZN · Pharmaceutical Preparations

Vanda Pharmaceuticals Inc.

VNDA · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Jazz Pharmaceuticals plc (JAZZ) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo